PDCD1 and non-small cell lung carcinoma: ICIs have been shown to effectively enhance pre-existing anti-tumour immune-responses among multiple immune-active cancer types such as melanoma, non-small cell lung cancer, and renal cell carcinoma (6–8).Accordingly, anti-PD1 antagonistic antibodies (pembrolizumab and nivolumab, resp).